Inhaled and Intranasal Products: Contract Service Providers Market (Focus on Drugs and Drug Delivery Systems), 2020 – 2030

Inhaled and Intranasal Products: Contract Service Providers Market (Focus on Drugs and Drug Delivery Systems), 2020 – 2030

Over the past few decades, the prevalence of respiratory disorders has been increasing at an alarming rate. In fact, each year around 7 million deaths are attributed to respiratory disorders caused by air pollution, worldwide. , Moreover, as per a Global Burden of Disease study, around 3 million fatalities are reported annually due to chronic obstructive pulmonary disorders (COPD). It is also important to note that, as of April 2020, an estimated 330 million individuals are suffering from asthma. , , Other causative factors responsible for respiratory diseases include smoking, climate change, low immunity, inappropriate development of lungs, and bacterial, viral and fungal infections. , It is worth mentioning that the novel SARS-CoV2 viral strain is a respiratory pathogen.

Targeting the delivery of drugs directly into the lungs is deemed to be the most effective way to ensure optimal therapeutic benefits while treating pulmonary disorders. In addition, this route of administration has also been shown to be effective for drugs intended to treat a variety of other conditions, including various metabolic (460+ million adults estimated to be living with diabetes) , hormonal, autoimmune, infectious diseases / disorders and mental health conditions (260 million individuals estimated to be suffering from depression and around 50 million have epilepsy, worldwide). , , As a result, innovators in the pharmaceutical industry are engaged in efforts to develop the means to formulate and administer pharmacological interventions via inhalation and / or the intranasal route. Since 2019, the FDA has approved multiple inhaled and intranasal drug products, namely TOSYMRA™ (migraine), NUMBRINO™ (local anesthetic), GIMOTI™ (diabetic gastroparesis), VALTOCO® (epilepsy), NAYZILAM® (epilepsy), DUAKLIR® PRESSAIR® (COPD), PROAIR® DIGIHALER™ (asthma and COPD), AIRDUO® DIGIHALER™ (asthma), SPRAVATO® (depression). , , , , , , , ,

Presently, several players are attempting to develop inhalable versions of different classes of drugs. In such endeavors, reformulating complex therapeutic molecules (such as biologics), novel drug classes (such as nanoparticle based medicine) and those intended for systemic delivery, present unique challenges. Further, the inhaled route of delivery itself has always been associated with several challenges, mostly related to ensuring the drug to its intended target. These concerns are further compounded by multiple physiological barriers, such as mucus hypersecretion / thickening, narrowing / collapse of airways, fibrosis and poor blood circulation.
In order to navigate through the aforementioned challenges, innovators prefer to rely on specialty service providers with expertise in inhaled and intranasal nasal medicine. Such players, given their experience and niche expertise, enable innovator companies to not only expedite product development and production timelines, but also offer cost saving opportunities as well. Further, such service providers generally have the necessary infrastructure to scale-up operations in order to meet the evolving needs of a business across different stages of product development. , Given the anticipated growth in demand for inhaled and intranasal drug products, the specialty contract services market catering to this segment of the pharmaceutical industry, is anticipated to witness substantial growth in the coming years.
SCOPE OF THE REPORT

The ‘Inhaled and Intranasal Products: Contract Service Providers Market (Focus on Drugs and Drug Delivery Systems), 2020 – 2030’ report features an extensive study of the current market landscape and future opportunities for the contract service providers focused on drugs and drug delivery systems. It features an in-depth analysis, highlighting the capabilities of various contract service providers engaged in this domain. Amongst other elements, the report includes:
A detailed assessment of the overall landscape of companies offering contract and custom services for the inhaled and Intranasal drug development and manufacturing, along with information on a number of relevant parameters, such as year of establishment, company size, type of service provider (contract manufacturing organization and contract research organization), scale of operation (preclinical, clinical and commercial), location of headquarters, location of manufacturing facilities, type of drug molecule (small molecule and biologic), type of inhaled and intranasal related primary service(s) offered (development, manufacturing, analytical testing / services, device selection / optimization and fill / finish and packaging), type of inhaled and intranasal related secondary service(s) offered (process development, pre-formulation development, formulation development, pre-formulation manufacturing, formulation manufacturing, particle engineering, product characterization, extractable and leachable studies, stability testing and plume geometry measurement), type of formulation (powder, aerosol and liquid), type of dosage form (metered dose inhaler, dry powder inhaler, nebulizer, soft mist inhaler, nasal spray, nasal drops, nasal powder and others), route of administration (oral and intranasal inhalation) and installed capacity and batch size (if available).
A detailed assessment of the overall landscape of the companies offering contract services for the inhaled and intranasal drug delivery system manufacturing, along with information on a number of relevant parameters, such as year of establishment, company size, scale of operation (precommercial and commercial), location of headquarters, location of manufacturing facilities, type of inhaled and intranasal drug delivery system related service(s) offered (design, development, manufacturing, assembly, fill / finish and packaging), type of formulation (powder, aerosol and liquid) and type of drug delivery system used (metered dose inhaler, dry powder inhaler, nebulizer, nasal spray and others).
A competitiveness analysis of inhaled and intranasal drug product contract service providers across key geographical areas, featuring a four-dimensional bubble representation, taking into consideration service strength (number of services offered, type of formulation(s) offered and route of administration), manufacturing strength (type of drug molecule, scale of operation, number of manufacturing facilities), supplier strength (company size and its experience in this field) and company size (small-sized, mid-sized and large).
Tabulated profiles of some of the key contract manufacturers (shortlisted based on a proprietary criterion) that offer a diverse range of capabilities for the development, manufacturing and packaging of inhaled and intranasal drugs across North America, Europe and Asia-Pacific. Each profile features an overview of the company, along with information related to its financial performance (if available), service portfolio, products and intranasal related capabilities, type of drug molecule, type of dosage form, inhaled and intranasal products related manufacturing facilities, recent developments and an informed future outlook.
An analysis of the various partnerships related to inhaled and intranasal contract service providers, which have been established since 2015, based on several parameters, such as year of agreement, type of partnership (development agreements, manufacturing agreements, merger and acquisition, licensing agreement, commercialization, research and development agreements, service alliance, joint venture and other agreements), scale of operation (preclinical, clinical and commercial), type of inhaled and intranasal related service(s) offered (development, manufacturing, analytical testing / services and fill / finish and packaging), type of dosage form (metered dose inhalers, dry powder inhalers, nebulizers and others) and most active players. It also provides the regional distribution of the players involved in the collaborations.
A qualitative analysis highlighting the various factors that need to be taken into consideration by inhaled and intranasal product developers, while deciding whether to manufacture their respective products in-house or engage a contract service provider.
An estimate of the global, inhaled and intranasal product demand, based on the type of product (inhaled and intranasal), type of drug delivery system used (metered dose inhalers, dry powder inhalers, nebulizers and nasal sprays) and key geographical regions (North America, Europe and Asia-Pacific).
An insightful discussion on the impact of COVID-19 outbreak on the inhaled and intranasal service providers. In addition, it features various strategies that different companies have adopted / may adopt in order to mitigate the challenges affiliated to the current global crisis.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as overall pulmonary market, global intranasal drug market, cost of goods sold and outsourcing trends, we have provided an informed estimate of the likely evolution of the contract service providers market in the mid to long term, for the time period 2020-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] scale of operation (clinical, commercial and both), [B] type of product manufacturing services offered (API manufacturing, end product manufacturing and others), [C] type of drug delivery system used (metered dose inhaler, dry powder inhaler, nebulizer and nasal spray), [D] route of administration (orally inhaled and intranasal) and [E] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In addition, specific to intranasal service providers, the market has been segmented by the type of drug class (corticosteroids, decongestants, antiallergic, anti-infectives and other topical preparations) and for inhalation service providers, the market has been segmented by the type of disease indication (asthma, COPD, diabetes, cystic fibrosis and others). In addition to the market forecast for inhaled and intranasal drugs, we have also provided a 10-year forecast for inhaled and intranasal drug delivery systems, covering the market of metered dose inhaler, dry powder inhaler, nebulizer and nasal spray. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry and non-industry players:
Ben Forbes (Professor, King’s College London)
Dries Cardoen (Team Leader of Study Directors, Nelson Laboratories)
Neeraj Kumar (Honorary Secretary, The Indian Pharmaceutical Association)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

KEY QUESTION ANSWERED
Who are the leading contract service providers offering inhalable and intranasal products related services, across the world?
In which regions are majority of the inhaled and intranasal product related manufacturing facilities located?
What percentage of inhaled and intranasal manufacturing operations are outsourced?
Which partnership models are commonly adopted by stakeholders in this industry?
What is the impact of COVID-19 outbreak on inhaled and intranasal product services market?
What is the current, global demand for inhaled and intranasal products?
How is the current and future market opportunity likely to be distributed across key market segments?

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market over the next decade, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the current state of inhaled and intranasal service providers market and its likely evolution in the short to mid-term and long term.

Chapter 3 provides a general introduction to inhaled and intranasal related drugs and drug delivery systems. The chapter also includes the historical evolution of inhaled and intranasal therapy. It features a brief overview of the type of inhalable and intranasal drug formulations, type of inhaled and intranasal drugs and delivery systems, assessment of quality and performance during inhaled and intranasal development, regulatory landscape, approved inhaled and intranasal products and importance of outsourcing in this domain. Further, the chapter also discusses the future perspective of the inhaled and intranasal service providers market.

Chapter 4 includes a detailed analysis of the current market landscape of over 110 drug based contract service providers, based on year of establishment, company size, type of service provider (contract manufacturing organization and contract research organization), scale of operation (preclinical, clinical and commercial), location of headquarters, location of manufacturing facilities, type of drug molecule (small molecule and biologic), type of inhaled and intranasal related primary service(s) offered (development, manufacturing, analytical testing / services, device selection / optimization and fill / finish and packaging), type of inhaled and intranasal related secondary service(s) offered (process development, pre-formulation development, formulation development, particle engineering, product characterization, extractable and leachable studies, stability testing and plume geometry measurement), type of formulation (powder, aerosol and liquid), type of dosage form (metered dose inhaler, dry powder inhaler, nebulizer, soft mist inhaler, nasal spray, nasal drops, nasal powder and others), route of administration (oral and nasal inhalation) and installed capacity and batch size (if available).

Chapter 5 includes a detailed includes a detailed analysis of the current market landscape of around 20 drug delivery system based contract manufacturers, year of establishment, company size, scale of operation (precommercial and commercial), location of headquarters, location of manufacturing facilities, type of inhaled and intranasal drug delivery system related service(s) offered (design, development, manufacturing, assembly, fill / finish and packaging), type of formulation (powder, aerosol and liquid) and type of drug delivery system used (metered dose inhaler, dry powder inhaler, nebulizer, nasal spray and others).

Chapter 6 presents a detailed competitiveness analysis of inhaled and intranasal products providers across the type of service providers and key geographical areas. It features a four-dimensional bubble representation, taking into consideration service strength (number of services offered, type of formulation(s) offered and route of administration), manufacturing strength (type of drug molecule, scale of operation, number of manufacturing facilities), supplier strength (company size and its experience in this field) and company size (small-sized, mid-sized and large).

Chapter 7 features tabulated profiles of some of the key contract manufacturers that are active in the inhaled and intranasal service providers market in North America. Each profile presents a brief overview of the company, along with information related to its financial information (if available), service portfolio, inhaled and intranasal related capabilities, type of drug molecule(s), type of dosage form(s), inhaled and intranasal products related manufacturing facilities and recent developments and an informed future outlook.

Chapter 8 features tabulated profiles of some of the key contract manufacturers that are active in the inhaled and intranasal service providers market in Europe and Asia-Pacific. Each profile presents a brief overview of the company, along with information related to its financial information (if available), service portfolio, inhaled and intranasal related capabilities, type of drug molecule(s), type of dosage form(s), inhaled and intranasal products related manufacturing facilities and recent developments and an informed future outlook.

Chapter 9 features in-depth analysis and discussion of the various partnerships inked between the players in this market, during the period, 2015-2020, covering analysis based on parameters such as year of agreement, type of partnership (development agreements, manufacturing agreements, merger and acquisition, licensing agreement, commercialization, research and development agreements, service alliance, joint venture and other agreements), scale of operation (preclinical, clinical and commercial), type of inhaled and intranasal related service(s) offered (development, manufacturing, analytical testing / services and fill / finish and packaging), type of dosage form (metered dose inhalers, dry powder inhalers, nebulizers and others) and most active players. It also provides the regional distribution of the players involved in the collaborations.

Chapter 10 presents a qualitative analysis that highlights the various factors that need to be taken into consideration by inhaled and intranasal product developers, while deciding whether to manufacture their respective products in-house or engage the services of a contract service organization.

Chapter 11 provides an overview of the demand for inhaled and intranasal products. The study examines the distribution of demand, based on the route of administration (orally inhaled and intranasal), type of drug delivery system used (metered dose inhalers, dry powder inhalers, nebulizers and nasal sprays) and key geographical areas (North America, Europe and Asia-Pacific).

Chapter 12 presents a comprehensive market forecast analysis, highlighting the likely growth of the inhaled and intranasal product service providers market, for the time period 2020-2030. In order to provide an informed future outlook, our projections have been segmented on the basis of [A] scale of operation (clinical, commercial and both), [B] type of product manufacturing services offered (API manufacturing, end product manufacturing and others), [C] type of drug delivery system used (metered dose inhaler, dry powder inhaler, nebulizer and nasal spray), [D] route of administration (orally inhaled and intranasal) and [E] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In addition, specific to intranasal service providers the market has been segmented by the type of drug class (corticosteroids, decongestants, antiallergic, anti-infectives and other topical preparations) and for inhalation service providers the segmentation has been done by the type of disease indication (asthma, COPD, diabetes, cystic fibrosis, other). In addition to the market forecast for inhaled and intranasal drugs, we have also provided a 10-year forecast for inhaled and intranasal drug delivery systems, covering the market of metered dose inhaler, dry powder inhaler, nebulizer and nasal spray.

Chapter 13 highlights the effect of coronavirus outbreak on the inhaled and intranasal service providers market. It includes a brief discussion on the short-term and long-term impact of COVID-19 on the supply chain and market opportunity for drug developers and contract service providers. In addition, it includes a brief section on strategies and action plans that pharma companies are likely to adopt in order to prepare for supply chain disruptions in future.

Chapter 14 summarizes the overall report. wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the inhaled and intranasal service providers market.

Chapter 15 is a collection of transcripts of interviews conducted with key stakeholders in the industry. In this chapter, we have presented the details of our conversations with Ben Forbes (Professor, King’s College London), Dries Cardoen (Team Leader of Study Directors, Nelson Laboratories) and Neeraj Kumar (Honorary Secretary, The Indian Pharmaceutical Association).

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 17 is an appendix, which contains the list of companies and organizations mentioned in the report.

LIST OF COMPANIES

1. 3M
2. 3P innovation
3. Actelion Pharmaceuticals
4. Aerami Therapeutics (formerly Dance Biopharm)
5. Aerosol Research and Engineering Laboratories
6. Akums Drugs & Pharmaceuticals
7. Alcami
8. Alpic Biotech
9. Altaris Capital Partners
10. Altimmune
11. Amneal Pharmaceuticals
12. Aptar Pharma
13. Arch Biopartners
14. Arcturus Therapeutics
15. ASM Aerosol-Service
16. Aspen Pharmacare
17. AstraZeneca
18. Atossa Therapeutics
19. Aurohealth
20. Basic Pharma
21. Battelle
22. Bespak
23. Beximco Pharmaceuticals
24. BioCare Group
25. Biofilms Research Center for Biointerfaces, Malmö University
26. Boehringer Ingelheim
27. Breath Therapeutics
28. Capsugel
29. Carclo Technical Plastics
30. Catalent
31. CF PharmTech
32. Charles River Laboratories
33. Chemic Laboratories
34. Chiesi Farmaceutici
35. Chromcore Lifesciences
36. Cirrus Pharmaceuticals
37. COC Farmaceutici
38. Colep
39. Confab
40. Consort Medical
41. Contract Pharmaceuticals
42. Creative Biolabs
43. Circassia
44. CrystecPharma
45. Curida
46. CytoAgents
47. Dalton Pharma Services
48. DFE Pharma
49. Doctor Pack
50. Dorizoe Lifesciences
51. DPT Laboratories
52. Dr. Reddy’s Laboratories
53. DRK Pharma Solutions
54. Dwarkesh Pharmaceuticals
55. EKG Life Science Solutions
56. Elfin Drugs
57. Emmace Consulting
58. Ennaid Therapeutics
59. Ethris
60. Eurofins
61. Evoke Pharma
62. Evonik
63. Experic
64. Farbe Firma
65. FAMAR
66. Focus Inhalation
67. Forefront Medical Technology
68. Forest Laboratories
69. Genentech
70. Gerresheimer
71. Getron Pharmaceuticals
72. Gilead Sciences
73. GlaxoSmithKline
74. Global Pharma
75. Hikma Pharmaceuticals
76. Horizon Pharmaceuticals
77. Hovione
78. Humanigen
79. Iconovo
80. IIT Research Institute (IITRI)
81. Impopharma
82. Importfab
83. Inhalexpert
84. InhaTarget Therapeutics
85. Insmed
86. Intas Pharmaceuticals
87. Intertek
88. Invion
89. iPharma
90. ITC Farma
91. J Pharmaceuticals
92. Jabil
93. Jagotec
94. Janssen Pharmaceuticals
95. Johnson & Johnson
96. Kiel University
97. Kindeva Drug Delivery
98. King’s College London
99. Kymos Pharma Services
100. Labiana Pharmaceuticals
101. Lamda Laboratories
102. Lannet Technologies
103. LEAX Group
104. Lepharm
105. Life Vision Healthcare
106. Lindal Group
107. Liquidia Technologies
108. Lomapharm
109. Lonza
110. Lovelace Biomedical
111. Lxir Medilabs (A unit of SMM Life Sciences)
112. M2M Pharmaceuticals
113. Macter International
114. Malmö University
115. MannKind
116. Mapaex
117. Maya Biotech
118. McMaster University
119. Medicair Bioscience Laboratories
120. Medicilon
121. Medlab Pharmaceuticals
122. MedPharm
123. Menarini Group
124. Merck
125. Micro-Sphere
126. MidasCare
127. Mipharm
128. MMG Healthcare
129. Moderna Therapeutics
130. Molex
131. Medicon Valley Inhalation Consortium (MVIC)
132. Mylan
133. Nanologica
134. Nanopharm
135. Napp Pharmaceuticals
136. Nelipak Healthcare Packaging
137. Nelson Laboratories
138. Nemera
139. Nephron Pharmaceuticals
140. Neurelis
141. Neurimmune
142. Newtec Pro Manufacturing
143. Next Breath
144. Nipro
145. Nitto Medic
146. Nivon Specialties
147. Noble
148. Novartis
149. One Pharma
150. Orion
151. Oté Pharma
152. Optinose
153. Paragon Nordic
154. PARI Pharma
155. PCI Pharma Services
156. Penta Arzneimittel
157. Pfizer
158. Pharma Stulln
159. Pharma Tech
160. PharmaCielo
161. Pharmaserve
162. Pharmaterials
163. PHAST (Acquired by Eurofins)
164. Phillips-Medisize
165. Pine Lake Laboratories
166. Polyphor
167. PPD Laboratories
168. Probiotec
169. Propeller Health
170. Proveris Scientific
171. Pulmatrix
172. PulmoFlow
173. Pursuit Pharma
174. Pushkar Pharma
175. Quotient Sciences
176. Recipharm
177. Renaissance Pharmaceuticals
178. Roche
179. Rommelag
180. Rubicon Research
181. S.R.Chemicals and Pharmaceuticals
182. SAFE Pharmaceutical
183. Salvat
184. Sandoz
185. Sanofi
186. Sciarra Laboratories
187. Seikagaku
188. Sentiss Pharma
189. Servier Pharmaceuticals
190. SHL Group
191. Simpler Consulting
192. SkyePharma
193. Smithers
194. Spicona
195. Stabicon Life Sciences
196. Stevanato Group
197. Summit Biosciences
198. Sunovion
199. Sunovion Pharmaceuticals
200. Synerlab
201. Takeda
202. Teva Pharmaceuticals
203. The Indian Pharmaceutical Association
204. The Ritedose Corporation
205. Theravance Biopharma
206. Tinuum
207. Toxikon
208. Trillium Health Care Products
209. UCB Pharma
210. Ultratech India
211. United Therapeutics
212. University of Birmingham
213. University of Copenhagen
214. University of Cyprus
215. University of Florida
216. University of Turku
217. Bausch Health (formerly Valeant Pharmaceuticals)
218. Vectura
219. ViralClear Pharmaceuticals (A subsidiary of BioSig Technologies)
220. Vinventions
221. Vivimed
222. West Coast Pharmaceutical
223. Westmed Medical Group

Please note that the publisher limits purchases by consulting clients to either Consulting Company Team License or Global Site License for Entire Company. Any other selections will not be fulfilled by this publisher.